Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P980023/S140

Ilivia Neo 7 VR-T DX 429530; Intica Neo 7 VR-T DX 429559; Intica Neo 5 VR-T DX 429569

Biotronik, Inc. · Decision date Sep 25, 2026

MEDTECHLEDGER EXPLANATIONP980023/S140

What did the FDA approve?

The FDA decision P980023/S140, dated 2026-09-25, is an approval of a supplement to PMA P980023 under the Normal 180 Day Track. The recorded supplement reason is "Change Design/Components/Specifications/Material," and the applicant is Biotronik, Inc. The listed products are Ilivia Neo 7 VR-T DX 429530, Intica Neo 7 VR-T DX 429559 and Intica Neo 5 VR-T DX 429569, in the implantable cardioverter defibrillator (non-CRT) category (product code LWS). The identifier ties this action to the original P980023 approval as a supplement rather than a separate original PMA.

The supplied statement refers to "the next generation of the Home Monitoring Service Center (HMSC)" without identifying which design, component, specification or material changed, or how the change relates to the listed devices. That purpose is a reported statement in the record, not independent evidence of safety or clinical effectiveness, and the field label alone does not establish the technical scope of the change.

FDA approval order statement

the next generation of the Home Monitoring Service Center (HMSC)
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Cardiovascular
Decision date
Sep 25, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P980023/S140
Regulatory pathway
PMA supplement
Product code
LWS
Decision code
APPR
Decision date
Sep 25, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implantable cardioverter defibrillator (non-CRT).

Product code
LWS
FDA device class
3

For the original device and its historical approval scope, see PMA P980023. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P980023 · Original PMA

    PHYLAX IMPLANTABLE CARDIOVERTER DEFIBRILLATOR SYSTEM

  2. P980023/S140 received

    Application receipt date recorded by FDA.

  3. P980023/S150 · Related supplement

    Pamira S 60; Pamira S 65; Pamira S 75; Pamira SD 60/16; Pamira SD 65/16; Pamira SD 65/18; Pamira SD 75/18; Pamira S DX 6

  4. P980023/S146 · Related supplement

    Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Rivacor Aura VR-T, Acticor Sky VR-T DX, Rivacor Sky VR-T DX, Riva

  5. P980023/S151 · Related supplement

    Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Rivacor Aura VR-T, Acticor Sky VR-T DX, Rivacor Sky VR-T DX, Riva

  6. P980023/S140 · FDA decision

    Normal 180 Day Track

  7. P980023/S149 · Related supplement

    Acticor Sky VR-T 481989; Rivacor Sky VR-T 481984; Rivacor Rise VR-T 482020; Rivacor Aura VR-T 482015; Acticor Sky VR-T D

  8. P980023/S152 · Related supplement

    Ilivia Neo 7 VR-T DX DF-1 ProMRI, Ilivia Neo 7 VR-T DF-1 ProMRI, Intica Neo 7 VR-T DX DF-1 ProMRI, Intica Neo 7 VR-T DF-

  9. P980023/S153 · Related supplement

    Ilivia Neo 7 VRT DX, Intica Neo 7 VRT DX, Intica Neo 5 VRT DX, Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Ri

Timeline entries are records held by MedtechLedger for P980023. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P980023

Explore the linked device profile

Other records with product code LWS

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biotronik, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6024 Jean Rd., Lake Oswego, OR, 97035

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records